EGFR and non-small cell lung carcinoma: Although some studies have shown spironolactone exerts its anticancer effects by inhibiting DNA repair, thereby augmenting DNA-damaging drugs, a recent report demonstrated spironolactone’s synergy with non-genotoxic EGFR inhibitor osimertinib as well as to gemcitabine in both GB and in NSCLC cells [110].